Regenxbio (RGNX) Misses Q2 EPS by 2c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Regenxbio Inc. (RGNX) PT Lowered to $100 at Chardan Capital Markets, Following Drug Trial Update
August 4, 2020 2:36 PM EDTChardan Capital Markets analyst Gbola Amusa lowered the price target on Regenxbio Inc. (NASDAQ: RGNX) to $100.00 (from $150.00) while maintaining a Buy rating.
... MoreRegenxbio (RGNX) Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD
August 4, 2020 7:10 AM EDTCompany on track to initiate RGX-314 subretinal delivery pivotal program by the end of 2020RGX-314 was generally well-tolerated in 42 patients at all dose levels in Phase I/IIa trialPositive interim update from Cohorts 4 and 5 at one year informs pivotal program Durable treatment effect observed with stable to improved visual acuity and retinal thickness Demonstrated meaningful reductions in anti-VEGF treatment burden over one year 61% and 85% reduction of anti-VEGF injections in Cohorts 4 and 5, respectively73% of patients (8/11) in Cohort 5 remain anti-VEGF... More
